Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02511262 · ClinicalTrials.gov registry record
Detection of Mycoplasma Pneumoniae
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 471
- Enrollment target
NCT02511262 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 471 participants.
The verdict
NCT02511262 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 471 participants
- Enrollment target
Study Summary
The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.
Interventions
- DEVICE illumigene® Mycoplasma Direct, illumipro-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2015-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02511262
The ClinicalTrials.gov registry entry for NCT02511262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which illumigene® Mycoplasma Direct, illumipro-10 is the first listed.
NCT02511262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02511262 about?
NCT02511262 is a clinical study titled "Detection of Mycoplasma Pneumoniae". The objective of this Clinical Trial is to define the methods to be used to document that illumigene® Mycoplasma Direct meets its intended use claims, using the illumipro instrument, with throat swab samples collected from symptomatic patients.
What is the current status of trial NCT02511262?
This trial is currently completed. The enrollment target is 471 participants. The study started on 2015-08.
What interventions are being tested in trial NCT02511262?
The interventions under investigation include: illumigene® Mycoplasma Direct, illumipro-10 (DEVICE).
Who is sponsoring clinical trial NCT02511262?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.